- 2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023
- Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023
- Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
The number of "Tik Tok refugees" on Xiaohongshu has surged, leading to a spike in A-share Concept stocks! What related symbols are there in the Hong Kong stock market?
Futu Daily | Core CPI cooling "ignites" stocks, bonds, and currencies! Federal Reserve officials comment: Inflation will decline, and interest rate cuts depend on the data; shutting down on Sunday? Trump is considering signing an executive order to suspen
Market orgy! The US core CPI unexpectedly cooled down, and hopes for the Fed to cut interest rates during the year were revived? A quick look at Wall Street's first-line interpretation
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
Castle Biosciences Reports Preliminary 2024 Results: Expects $320M-$330M In Annual Revenue (+50% YoY), 96,071 Total Tests Delivered (+36% YoY), And $293M In Cash And Investments
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 227
Write a comment
Comment(0)
Reason For Report